sanofi (photo credit: Adobe Stock / )
(CercleFinance.com) – Sanofi announces that its Dupixent could become the first biological drug against chronic obstructive pulmonary disease (COPD), after a pivotal phase III study showing a significant reduction in exacerbations, compared to a placebo.
In adults on maximum standard inhaled therapy (triple therapy) with uncontrolled COPD with type 2 inflammatory signature, the product met its primary endpoint and all of its secondary endpoints.
Dupixent has thus made it possible to obtain a 30% reduction in acute moderate or severe exacerbations of COPD, as well as significant improvements in respiratory function, quality of life and respiratory symptoms due to this disease.
COPD, the third leading cause of death worldwide and for which no new treatment has been approved for more than ten years, is the seventh disease in which Dupixent has shown positive results in a pivotal clinical trial.